NEW YORK (GenomeWeb) – Prenetics, a Hong Kong-based pharmacogenomics firm, announced today that it has raised $10 million through a Series A financing round.

The round was led by Ping An Ventures, the VC arm of China's Ping An Insurance Group. Other investors included Venturra Capital and Capital Union Investments, as well as existing investors 500 Startups and Coent Venture Partners.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.